Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease
A legfontosabb adatok
- Ki végzi
- University Hospital, Basel, Switzerland
- Hol
- Basel (Svájc)A helyszín megnézéseMég 1 másik országban, 1 helyszínen
- Azonosító
- Állapot
- Csak meghívásos
- Résztvevők
- 43 fő, tervezett
- Kezdés
- 2026. jún. 4.
- Várható befejezés
- 2029. júl. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- [18F]FET PET-MRI
- A regiszteradat frissítve
- 2026. július 6.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with high cortisol levels driven by the hormone ACTH. Doctors need to find out if a small pituitary tumour or a source elsewhere in the body is causing it.
- Életkor
- 18 years and older
- Nem
- All sexes
- A betegség stádiuma
- Lab tests confirm ACTH-dependent high cortisol. ACTH is not suppressed and at least 2 of these tests are abnormal: overnight 1mg dexamethasone test > 50 nmol/L, high late-night saliva cortisol (at least 2 of 3 measurements), high 24-hour urine cortisol (at least 2 measurements). Standard pituitary MRI shows a tumour under 10mm, or nothing clear. Doctors plan a further test called IPSS (blood sampling from veins near the pituitary).
- Korábbi kezelés
- People using glucocorticosteroid (steroid) medicines cannot join.
- Biomarker vagy leletérték
- Non-suppressed ACTH levels plus at least 2 abnormal cortisol tests.
A részvétel fő kizáró okai
- High cortisol not caused by ACTH
- Pituitary tumour 10mm or larger
- Suspected pseudo-Cushing's, for example from alcohol use disorder, PCOS, obesity or depression
- Poor kidney function (eGFR under 30ml/min/1,73 m2) or poor liver function
- Pregnancy, breastfeeding, or known allergy to radioactive tracer medicines
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥18 years
- Biochemically confirmed ACTH-dependent hypercortisolism, defined as:
- Non-suppressed ACTH levels plus minimal 2 of the following:
- Overnight 1mg dexamethasone suppression test > 50 nmol/L
- Elevated late night salivary cortisol (min. 2/3 measurements)
- Elevated 24-hours urinary free cortisol (min. 2 measurements)
- Pituitary microadenoma (< 10mm) OR negative / inconclusive findings on standard MRI of the pituitary sella-region
- Indication for further evaluation with IPSS
Ki nem vehet részt
- Suspicion of Pseudo-Cushing's disease (e.g. due to alcohol use disorder, PCO's, obesity, de-pression) according to standard work up / guidelines
- Known allergic reaction to therapeutic radiopharmaceuticals
- Impaired renal function, defined as eGFR (MDRD) <30ml/min/1,73 m2. An exception can be made in consultation with the treating physician
- Non-ACTH dependent hypercortisolism
- Pituitary macroadenoma (≥ 10mm)
- use of glucocorticosteroids
- Impaired Liver function
- Pregnancy/breastfeeding. For the latter, temporary discontinuation may be considered
Helyszínek itt: Svájc
Még 1 másik országban, 1 helyszínen
- University Hospital BaselBasel, SvájcCsak meghívásos
A vizsgálatról
Mit akar kideríteni a vizsgálat
In ACTH-dependent hypercortisolism it is important to distinguish between Cushing's disease (CD), with ACTH production by a pituitary neuroendocrine tumour (PitNET) and Cushing's syndrome (CS), with ectopic ACTH production. Bilateral inferior petrosal sinus sampling (IPSS) is the gold standard for this distinction, with a diagnostic accuracy of 98%. However, IPSS is an invasive procedure and an indi-rect diagnostic method, rarely providing reliable data on the exact location of the PitNET. This has a major impact on the therapeutic approach, short and long-term remission rates, and other outcomes. Hybrid Positron-emission tomography-Magnetic Resonance Imaging (PET-MRI) using O-(2-[18F]-fluo-roethyl)-L-tyrosine ([18F]FET) is promising in this respect. Recent data published by our research group demonstrate a a sensitivity of 100% a high accuracy in in the precise localization of ACTH-secreting PitNETs. We hypothesize that [18F]FET PET-MRI could become the new non-invasive diagnostic stand-ard, but data regarding a direct comparison between the diagnostic impact of [18F]FET PET-MRI versus IPSS in the differentiation between CD and ectopic CS are lacking. In addition, there are currently no other reliable biomarkers to distinguish the two disorders. The investigators hypothesize that the ACTH-dependent biomarker copeptin could be a valuable addition in this regard. The aim of this prospective diagnostic study is to compare the diagnostic accuracy of [18F]FET-PET-MRI and IPSS in differentiating CD from ectopic CS in patients with ACTH-dependent hypercortisolism.
A vizsgálat csoportja
- [18F]FET-PET-MRI vs IPSS for diagnosing CD vs ectopic CS in ACTH-dependent casesEgyéb csoport
Participants will undergo both \[18F\]FET-PET-MRI and inferior petrosal sinus sampling (IPSS) to evaluate their diagnostic performance in differentiating Cushing's disease from ectopic ACTH secretion. Results of both procedures will be made available to the treating medical team and participants as they become available.
Kezelés: [18F]FET PET-MRI
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease - a Prospective Diagnostic Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. július 6.